Viral Vector Manufacturing Market Size, Share, & Trends by 2030

Viral Vector Manufacturing Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis By Type (Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others), Disease Indication (Cancer, Genetic Disorders, Infectious Disease, and Others), Application (Therapeutics Development, Vaccine Development, and CDMOs & CROs), End User (Pharmaceutical and Biotechnology Companies, Research Institutes, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

  • Report Code : TIPRE00038970
  • Category : Biotechnology
  • No. of Pages : 150
Buy Now

Viral Vector Manufacturing Market Size, Share, & Trends by 2030

Buy Now

[Research Report] The viral vector manufacturing market is projected to grow from US$ 1.29 billion in 2022 to US$ 5.00 billion by 2030; the market is estimated to record a CAGR of 18.4% during 2022–2030.

Market Insights and Analyst View:

Viral vectors help deliver genetic material into cells. Various types of viral vectors can be used to carry nucleic acids into the genetic composition of cells, including lentivirus, adenovirus, retrovirus, and adeno-associated virus, each with its own set of benefits and drawbacks for certain applications. Viral vectors are used in gene and cell therapy as a basis for prophylactic and therapeutic vaccines. Key factors driving the market growth are increasing clinical studies and development of viral-vector therapeutics and increasing demand for gene therapy. However, the complex viral-vector development process hinders the viral vector manufacturing market growth. Furthermore, technological advancements and strategic activities by viral vector manufacturers are expected to bring new viral vector manufacturing market trends in the coming years.

Growth Drivers and Restraints:

Recent developments in cell and gene therapies have made it feasible to treat various illnesses, including congenital disorders and cancer, which increases the viral vector manufacturing market size. According to the study “Gene therapy clinical trials, where do we go?” published in September 2022 in Elsevier Journal, the first gene therapy product, Gendicine, was approved for head and neck cancer after ~686 clinical trials by the Chinese State Food and Drug Administration (SFDA). In 2012, the clinical trials were doubled with the approval of Glybera by the European Medicines Agency (EMA), which indicated lipoprotein lipase deficiency. Similarly, in 2017, the FDA approved two chimeric antigen receptor (CAR) products—Kymriah and Yescarta. Furthermore, in 2019, Zolgensma (the most expensive drug to date), an adeno-associated viral vector (AAV) applied while performing gene therapies to treat pediatric spinal muscular atrophy, was approved by FDA.

Similarly, the US Food and Drug Administration (FDA) has approved many viral vector-based gene therapies over recent years. According to the FDA Office of Tissues and Advanced Therapies (OTAT), as of August 2023, more than 30 viral vector therapy products have been approved by the FDA. Similarly, according to Evaluate Pharma, as of February 2023, ~120 viral-vector therapeutics are in Phase II trials. Thus, a significant increase in approved gene therapy products and viral vector-based gene therapies each year boosts the viral vector manufacturing market size.

However, developing viral vectors is a complex process involving challenges in viral vector production and quality control measures. The production of viral vectors requires specialized equipment and facilities with adherence to good manufacturing practices (GMP) practices and other regulatory standards to ensure the final product's purity, safety, and efficacy. This can pose significant challenges for manufacturers, especially smaller companies or new entrants, owing to limited resources and expertise to meet these requirements. Furthermore, large-scale viral-vector manufacturing faces various other challenges, such as the incompatibility of production systems, which may impact different stages of viral vector development.

According to Patheon (service brand of Thermo Fisher Scientific), commercialization of viral vectors requires regulatory considerations to mitigate unnecessary risks such as compressed timelines, assay challenges and variability, raw materials using tumorigenic cell lines, and limited batches available at commercial scale. Thus, the complex viral vector development process hinders the viral vector manufacturing market expansion.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Viral Vector Manufacturing Market: Strategic Insights

viral-vector-manufacturing-market
Market Size Value inUS$ 1.29 billion in 2022
Market Size Value byUS$ 5.00 billion by 2030
Growth rateCAGR of 18.4% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The “viral vector manufacturing market analysis” has been carried out by considering the following segments: type, disease indication, application, and end user. Based on type, the market is differentiated into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. By disease indication, the market is segmented into cancer, genetic disorders, infectious diseases, and others. In terms of application, the market is differentiated into therapeutic development, vaccine development, and research. Based on end user, the viral vector manufacturing market is segmented into pharmaceutical & biotechnology companies, research institutes, and CDMOs & CROs. Geographically, the market is primarily divided into North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

Based on type, the market is differentiated into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. The adeno-associated viral vectors segment held the largest viral vector manufacturing market share in 2022. The lentiviral vectors segment is anticipated to register the highest CAGR during 2022–2030.

Based on disease indication, the viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and others. The cancer segment held the largest market share in 2022, and the genetic disorders segment is anticipated to register the highest CAGR from 2022 to 2030.

By application, the market is differentiated into therapeutics development, vaccine development, and research. In 2022, the vaccine development segment held the largest market share, and the therapeutics development segment is anticipated to register the highest CAGR during 2022–2030.

In terms of end user, the market is segmented into pharmaceutical & biotechnology companies, research institutes, and CDMOs & CROs. The pharmaceutical & biotechnology companies segment is anticipated to hold a significant viral vector manufacturing market share during 2022–2030.

Regional Analysis:

The scope of the global viral vector manufacturing market report focuses on North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In terms of revenue, North America dominated the viral vector manufacturing market share. The developments in medical infrastructure, the prevalence of cancer and genetic disorders, and the increasing expenditure on healthcare services across the US are the key factors, driving the growth of the market in the country. For instance, according to the American Cancer Society estimates, in 2022, ~1.9 million new cancer cases were diagnosed and more than 609,000 cancer deaths were reported in the US. Thus, the use of viral vectors in clinical trials, vaccine development, and biomedical research for cancer treatment and other diseases will substantially impact the viral vector manufacturing market growth.

Industry Developments and Future Opportunities:

The viral vector manufacturing market forecast can help stakeholders in this marketplace plan their growth strategies. A few initiatives taken by key players operating in the market are listed below:

  1. In July 2023, Biovian Oy announced an expansion of its manufacturing facility in Turku, Finland. The company announced a major investment of over €50 million (~US$ 55) for a facility with an area of 69,000 sq. ft. The facility houses advanced technologies and cutting-edge equipment to support the development and manufacturing of advanced therapy medicinal products, such as adenoviral and adeno-associated viral vector (AAV) therapies. The manufacturing facility also features dedicated Class A to D cleanroom areas for bulk drug materials and final drug product manufacture.
  2. In May 2023, AGC Biologics, the leading biopharmaceutical contract development and manufacturing organization (CDMO) in the world, launched two viral vector platforms: BravoAAV and ProntoLVV. AGC Biologics' innovative platforms provide quick, effective, and repeatable clinical and commercial GMP production and release by utilizing their combined 30 years of experience in the development, manufacturing, and analyses of lentiviral vector (LVV) and AAVs. The CDMO can offer GMP products in nine months because of its patented methodology and capsid-specific platform approaches, which can shorten development time.
  3. In March 2023, Catalent announced the expansion of its UpTempo platform process for the development and CGMP manufacturing of AAVs. Catalent is a global pioneer in facilitating the discovery and provision of better patient medicines. The platform now comprises an in-house, clonal HEK293 cell line and commercial plasmids to facilitate a strong supply chain for the research and production of gene therapies and accelerate the duration of first-in-human clinical assessment.
  4. In March 2023, Vector Biolabs announced the completion of a facility expansion. The newly constructed facility has office space, warehouses, QC labs, and a cleanroom manufacturing suite. With the extra capacity, vector will be able to continue providing its fast response times even as field demand grows and expand its offering to include new product characterization and quality control services.
  5. In August 2022, Merck became one of the first CDMOs and technology developers to offer a complete viral vector manufacturing offering, including AAV, Lentiviral, CDMO, CTO, and process development, with the introduction of the VirusExpress 293 AAV Production Platform. Due to this new platform, biopharmaceutical businesses can now accelerate clinical manufacturing while minimizing costs and time associated with process development.
  6. In September 2020, OXGENE officially launched their scalable, plasmid-free AAV manufacturing method. OXGENE's recently developed TESSA technology resolves industry-wide issues related to reliable and consistent AAV production on a large scale.

Viral Vector Manufacturing Market Report Scope

Competitive Landscape and Key Companies:

Charles River Laboratories, Merck KGaA, Biovian Oy, Global Life Sciences Solutions USA LLC, Lonza Group Ltd, Creative Biogene, VIVEbiotech SL, Genezen Laboratories Inc, GenScript Biotech Corporation, and AGC Biologics are among the prominent players operating in the viral vector manufacturing market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Disease Indication, Application, End User, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Who are the major players in the viral vector manufacturing market?

The viral vector manufacturing market majorly consists of the players, including Charles River Laboratories, Merck KGaA, Biovian Oy, Global Life Sciences Solutions USA LLC, Lonza Group Ltd, Creative Biogene, VIVEbiotech SL, Genezen Laboratories Inc, GenScript Biotech Corporation, and AGC Biologics

What factors drive the viral vector manufacturing market?

Key factors driving the viral vector manufacturing market growth are increasing clinical studies and development of viral-vector therapeutics and increasing demand for gene therapy.

What was the estimated viral vector manufacturing market size in 2022?

The viral vector manufacturing market was valued at US$ 1.29 billion in 2022.

Which type segment dominates the viral vector manufacturing market?

Based on type, the viral vector manufacturing market is differentiated into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. The adeno-associated viral vectors segment held the largest market share in 2022. The lentiviral vectors segment is anticipated to register the highest CAGR during 2022–2030.

What is viral vector manufacturing?

Viral vectors help deliver genetic material into cells. Various types of viral vectors can be used to carry nucleic acids into the genetic composition of cells, including lentivirus, adenovirus, retrovirus, and adeno-associated virus, each with its own set of benefits and drawbacks for certain applications. Viral vectors are used in gene and cell therapy as a basis for prophylactic and therapeutic vaccines.

Which end user segment dominates the viral vector manufacturing market?

In terms of end user, the viral vector manufacturing market is segmented into pharmaceutical & biotechnology companies, research institutes, and CDMOs & CROs. In 2022, the pharmaceutical & biotechnology companies segment held the largest market share and is anticipated to register the highest CAGR during 2022–2030.

Which application segment dominates the viral vector manufacturing market?

By application, the viral vector manufacturing market is differentiated into therapeutics development, vaccine development, and research. In 2022, the vaccine development segment held the largest market share, and the therapeutics development segment is anticipated to register the highest CAGR during 2022–2030.

What are the growth estimates for the viral vector manufacturing market till 2030?

The viral vector manufacturing market is expected to be valued at US$ 5.00 billion in 2030.

Which disease indication segment dominates the viral vector manufacturing market?

Based on disease indication, the viral vector manufacturing market is segmented into cancer, genetic disorders, infectious disease, and others. The cancer segment held the largest market share in 2022, and the genetic disorders segment is anticipated to register the highest CAGR from 2022 to 2030.

1. Introduction

1.1 Scope of the Study

1.2 Market Definition, Assumptions and Limitations

1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness Analysis

3. Research Methodology

4. Viral Vector Manufacturing Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Viral Vector Manufacturing Market - Key Market Dynamics

5.1 Key Market Drivers

5.2 Key Market Restraints

5.3 Key Market Opportunities

5.4 Future Trends

5.5 Impact Analysis of Drivers and Restraints

6. Viral Vector Manufacturing Market - Global Market Analysis

6.1 Viral Vector Manufacturing - Global Market Overview

6.2 Viral Vector Manufacturing - Global Market and Forecast to 2030

7. Viral Vector Manufacturing Market – Revenue Analysis (USD Million) – By Type, 2020-2030

7.1 Overview

7.2 Adenoviral Vectors

7.3 Adeno-Associated Viral Vectors

7.4 Lentiviral Vectors

7.5 Retroviral Vectors

7.6 Other Types

8. Viral Vector Manufacturing Market – Revenue Analysis (USD Million) – By Disease Indication, 2020-2030

8.1 Overview

8.2 Cancer

8.3 Genetic Disorders

8.4 Infectious Disease

8.5 Others

9. Viral Vector Manufacturing Market – Revenue Analysis (USD Million) – By Application, 2020-2030

9.1 Overview

9.2 Therapeutics Development

9.3 Vaccine Development

9.4 Research

10. Viral Vector Manufacturing Market – Revenue Analysis (USD Million) – By End User, 2020-2030

10.1 Overview

10.2 Pharmaceutical and Biotechnology Companies

10.3 Research Institutes

10.4 CDMOs & CROs

11. Viral Vector Manufacturing Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis

11.1 North America

11.1.1 North America Viral Vector Manufacturing Market Overview

11.1.2 North America Viral Vector Manufacturing Market Revenue and Forecasts to 2030

11.1.3 North America Viral Vector Manufacturing Market Revenue and Forecasts and Analysis - By Type

11.1.4 North America Viral Vector Manufacturing Market Revenue and Forecasts and Analysis - By Disease Indication

11.1.5 North America Viral Vector Manufacturing Market Revenue and Forecasts and Analysis - By Application

11.1.6 North America Viral Vector Manufacturing Market Revenue and Forecasts and Analysis - By End User

11.1.7 North America Viral Vector Manufacturing Market Revenue and Forecasts and Analysis - By Countries

11.1.7.1 United States Viral Vector Manufacturing Market

11.1.7.1.1 United States Viral Vector Manufacturing Market, by Type

11.1.7.1.2 United States Viral Vector Manufacturing Market, by Disease Indication

11.1.7.1.3 United States Viral Vector Manufacturing Market, by Application

11.1.7.1.4 United States Viral Vector Manufacturing Market, by End User

11.1.7.2 Canada Viral Vector Manufacturing Market

11.1.7.2.1 Canada Viral Vector Manufacturing Market, by Type

11.1.7.2.2 Canada Viral Vector Manufacturing Market, by Disease Indication

11.1.7.2.3 Canada Viral Vector Manufacturing Market, by Application

11.1.7.2.4 Canada Viral Vector Manufacturing Market, by End User

11.1.7.3 Mexico Viral Vector Manufacturing Market

11.1.7.3.1 Mexico Viral Vector Manufacturing Market, by Type

11.1.7.3.2 Mexico Viral Vector Manufacturing Market, by Disease Indication

11.1.7.3.3 Mexico Viral Vector Manufacturing Market, by Application

11.1.7.3.4 Mexico Viral Vector Manufacturing Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe

11.2.1 Germany

11.2.2 France

11.2.3 Italy

11.2.4 Spain

11.2.5 United Kingdom

11.2.6 Rest of Europe

11.3 Asia-Pacific

11.3.1 Australia

11.3.2 China

11.3.3 India

11.3.4 Japan

11.3.5 South Korea

11.3.6 Rest of Asia-Pacific

11.4 Middle East and Africa

11.4.1 South Africa

11.4.2 Saudi Arabia

11.4.3 U.A.E

11.4.4 Rest of Middle East and Africa

11.5 South and Central America

11.5.1 Brazil

11.5.2 Argentina

11.5.3 Rest of South and Central America

12. Industry Landscape

12.1 Mergers and Acquisitions

12.2 Agreements, Collaborations, Joint Ventures

12.3 New Product Launches

12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players

13.2 Company Positioning and Concentration

14. Viral Vector Manufacturing Market - Key Company Profiles

14.1 Charles River Laboratories

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

14.2 Merck KGaA

14.3 Biovian Oy

14.4 Global Life Sciences Solutions USA LLC

14.5 Lonza Group Ltd

14.6 Creative Biogene

14.7 VIVEbiotech SL

14.8 Genezen Laboratories Inc

14.9 GenScript Biotech Corporation

14.10 AGC Biologics

15. Appendix

15.1 Glossary

15.2 About The Insight Partners

15.3 Market Intelligence Cloud

The List of Companies - Viral Vector Manufacturing Market 

  1. Charles River Laboratories
  2. Merck KGaA
  3. Biovian Oy
  4. Global Life Sciences Solutions USA LLC
  5. Lonza Group Ltd
  6. Creative Biogene
  7. VIVEbiotech SL
  8. Genezen Laboratories Inc
  9. GenScript Biotech Corporation
  10. AGC Biologics

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Biotechnology : READ MORE..